Low-Dose Single-Agent Weekly Docetaxel (Taxotere) is Effective and Well Tolerated in Elderly Men with Prostate Cancer.

Sub-category: Prostate Cancer
Category: Genitourinary Cancer
Meeting: 2001 ASCO Annual Meeting

Abstract No: 2441
Citation: Proc Am Soc Clin Oncol 20: 2001 (abstr 2441)
Author(s): Mark Creamer Scholz, Brad Guess, Fernando Barrios, Stephen Strum, Robert Leibowitz, Healing Touch Oncology, Marina del Rey, CA; Prostate Cancer Research Institute, Los Angeles, CA; Compassionate Oncology Medical Group, Century City, CA.

Abstract: Docetaxel (Taxotere) (TXT) has substantial activity against prostate cancer (PC). However many men with metastatic PC are elderly and tolerate chemotherapy poorly. Weekly TXT may have a more favorable toxicity profile than every 3-week TXT while retaining comparable anti-cancer activity. The results of two Phase II trials using TXT-based chemotherapy in stage D2 PC were retrospectively reviewed for effectiveness and toxicity. In one trial, TXT @ 25 mg/m² was administered weekly to 20 patients with no routinely scheduled off-weeks except for side effects or patient request. In the second trial, a combination of TXT @ 70mg/m² on day #1 and Emcyt 140 mg tid days 1-7 every 21 days was administered to 19 patients. The median patient characteristics for each study are shown below. The frequency and severity of lassitude, neuropathy, edema, anemia, rash, anorexia, and gustatory changes were similar in both groups. Alopecia, nausea, and neutropenia were more common in the 3-week group and thrombocytopenia was more common in the weekly group. Five patients on the every 3-week TXT + Emcyt protocol stopped treatment early for toxicity: Lassitude (3) Neuropathy (2) as did three men in the weekly TXT protocol: Lassitude (2) Neuropathy (1). PSA response rate, defined as 50% decline for at least 4 weeks was similar in both studies: 60% 3-week and 61% weekly. Mean time to progression was 6.8 months 3-week and 5.6 months weekly. Conclusion: Weekly low-dose Taxotere is a practical treatment alternative for aged men with metastatic PC.

PATIENT CHARACTERISTICS

<table>
<thead>
<tr>
<th>Regimen</th>
<th>Age</th>
<th>KPS</th>
<th>Bone Scan</th>
<th>PSA</th>
<th>PAP</th>
<th>No Prior Chemo</th>
<th>Alk Phos &gt; 2X Norm.</th>
</tr>
</thead>
<tbody>
<tr>
<td>TXT Weekly</td>
<td>76</td>
<td>80</td>
<td>2</td>
<td>338</td>
<td>36</td>
<td>85%</td>
<td>30%</td>
</tr>
<tr>
<td>TXT 3-Week</td>
<td>67</td>
<td>80</td>
<td>2</td>
<td>280</td>
<td>32</td>
<td>47%</td>
<td>16%</td>
</tr>
</tbody>
</table>

KPS = Karnofsky